Health Canada Adds New Tracking Features for Generic Reviews

Enhanced Transparency Features

The updated Submissions Under Review (SUR) system now displays the submission 'class' for all completed reviews, indicating whether applications were processed under standard Health Canada procedures or through the Access Consortium, an international regulatory cooperation initiative.

This change affects tracking for all drug categories, including the nine pending Ozempic generic applications currently under Health Canada review. The enhanced system provides clearer visibility into the regulatory pathway used for each submission.

Access Consortium Integration

The new classification system highlights submissions reviewed under the Access Consortium framework, which allows Health Canada to coordinate reviews with regulatory agencies in Australia, Singapore, Switzerland, and the United Kingdom. This international cooperation can potentially expedite certain drug approvals.

For generic Wegovy and Mounjaro applications, the classification will indicate whether manufacturers pursued standard generic review pathways or sought Access Consortium coordination.

Impact on Generic Semaglutide Tracking

The timing of this system update coincides with ongoing reviews of nine generic semaglutide applications from companies including:

• Sandoz Canada
• Apotex Inc.
• Teva Canada Limited
• Taro Pharmaceuticals
• Aspen Pharmacare

Canadian patients and healthcare providers can now use the generic semaglutide tracker alongside Health Canada's enhanced SUR system to monitor application progress with greater detail about review classifications.

Regulatory Timeline Context

Health Canada maintains a target 180-day review timeline for standard generic applications. The new classification system will help distinguish between applications following standard timelines versus those processed through expedited international coordination pathways.

This enhanced tracking comes as generic manufacturers prepare for potential market entry in mid-to-late 2026, pending Health Canada approval of their applications submitted following the January 4, 2026 patent expiry.

System Implementation Details

The March 20, 2026 update represents the latest enhancement to Health Canada's public transparency initiatives for drug reviews. The system now provides:

• Submission class designation for all completed reviews
• Access Consortium status where applicable
• Updated completion tracking for ongoing applications

Healthcare professionals and patients seeking coverage information can reference the insurance coverage checker for current generic availability and provincial coverage policies as applications progress through the enhanced review system.